Vara Imandi is a technology leader and Director of Partner Product Success at Salesforce, known for bridging legacy healthcare systems with modern AI through MuleSoft and Agentforce. His work focuses ...

Pfizer Inc. (NYSE:PFE) is among the drugmakers planning to raise prices on some medicines starting January 1. The increases will affect about 350 drugs, even as President Donald Trump has reached ...

Cybercriminals and state-sponsored hackers are increasingly exploiting Microsoft’s legitimate OAuth 2.0 device authorization process to hijack enterprise accounts, bypassing multifactor authentication ...

Multiple threat actors are compromising Microsoft 365 accounts in phishing attacks that leverage the OAuth device code authorization mechanism. Attackers trick victims into entering a device code on ...

A surge in phishing campaigns abusing Microsoft’s OAuth device code authorization flow has been observed with multiple threat clusters using the technique to gain unauthorized access to Microsoft 365 ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Matthew Herper covers ...

For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a ...

Every advance against cancer reveals the same truth: this is a disease that has “learned” to fight back. There are more than 200 types of cancer, and the biology of a tumor is constantly changing.

Acumen Capital Partners has landed a $125 million loan to refinance an industrial asset in Brooklyn that was formerly Pfizer’s headquarters. “630 Flushing stands as a premier industrial and ...

Pfizer is getting its hands on a promising weight management candidate. The company's recent deal with the U.S. government eliminates a major risk. The stock's valuation looks attractive right now.

Over a weekend in late September, the team of Pfizer PFE1.03%increase; green up pointing triangle officials working with the Trump administration on drug prices got a message: Clear your schedules.